Citius Pharmaceuticals Inc vs Omnicom Group Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while Omnicom Group Inc. trades at $84.99 (market cap $23.58B). The key difference: Omnicom Group Inc. is far larger — about 1178.4× Citius Pharmaceuticals Inc's market cap, and Omnicom Group Inc. pays a 3.72% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | OMC | |
|---|---|---|
Market Cap | $20.01M | $23.58B |
Sector | Health | Media |
52-Week High | $1.82 | $86.22 |
52-Week Low | $0.48 | $67.27 |
Enterprise Value | $16.23M | $31.66B |
Dividend Yield | — | 3.72% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Omnicom Group (OMC) trades at $85.34, up 0.82% today, with a bullish technical signal from moving averages and a consensus price target of $107.00. Recent Q2 2026 earnings beat expectations with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company shows strong cash flow from operations at $2.94 billion in 2025 and pays a $0.80 quarterly dividend.
Outlook is positive with post-merger synergies driving margin expansion, but high P/E of 232.3 and integration risks from the Interpublic acquisition pose challenges. Analyst sentiment is mixed with 32% buy ratings, highlighting value potential amid execution concerns. Key catalysts include sustained organic growth and cost savings realization.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →